Loading...

Mark Moasser, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-353-7070
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Tufts University, Boston, MAM.D.1988School of Medicine
    University of Pennsylvania, Philadelphia, PAB.A.1984Biophysics, Music
    New York Hospital - Cornell Medical Center, New York, NYResidency1991Internal Medicine
    Memorial Sloan-Kettering Cancer Center, New York, NYFellowship1995Medical Oncology

    Collapse Research 
    Collapse Research Activities and Funding
    A next-generation approach for inactivation of the HER2-HER3 tumor driver
    BCRF-AACR 218084Sep 1, 2012 - Aug 31, 2014
    Role: Principal Investigator
    Role Description: with David Agard
    Understanding the adaptational network underlying HER3 addiction
    California Breast Cancer Research Program 18IB-0030Aug 1, 2012 - Jul 31, 2013
    Role: Principal Investgator
    Towards highly effective inactivation of HER2-HER3 signaling
    California Breast Cancer Research Program 16OB-0150Jul 1, 2010 - Jun 30, 2014
    Role: Principal Investigator
    Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer
    Mary Kay Ash Charitable Foundation Mary Kay Ash Charitable FoundationDec 1, 2009 - Nov 30, 2011
    Role: Principle Investigator
    An integrated approach towards the eradication of HER2-driven breast cancer
    Susan G. Komen Foundation KG081684Jan 22, 2008 - Jan 21, 2010
    Role: Principal Investigator
    Role Description: with John Kuriyan & Jim Wells
    Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    NIH/NCI R21CA121108Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Understanding resistance in the HER2-HER3 tumor drive
    NIH/NCI R01CA122216Jul 1, 2006 - May 31, 2018
    Role: co-investigator
    Anatomic and Biologic Staging of Breast Disease with MRI
    NIH/NCI R01 CA069587Apr 1, 2006 - Nov 30, 2011
    Role: co-investigator
    HER3 infidelity and resistance to tyrosine kinase inhibitors
    California Breast Cancer Research Program 11IB-0069Aug 1, 2005 - Jun 30, 2007
    Role: Principal Investigator
    Promiscuous HER3 signaling; A new target in the treatment of breast cancer
    Susan G. Komen Foundation BCTR0504177May 1, 2005 - Apr 30, 2008
    Role: Principal Investigator
    Adhesion signaling by a novel mitotic substrate of src
    NIH/NCI R01CA113952Apr 1, 2005 - Feb 28, 2011
    Role: Principal Investigator
    Model-based predictions of responses to RTK pathway therapies
    NIH/NCI U54 CA112970Sep 30, 2004 - Feb 28, 2015
    Role: Co-investigator
    A novel mitotic phosphoprotein associated with src kinases
    American Cancer Society RSG-02-139-01-CDDJul 1, 2002 - Jun 30, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell Rep. 2018 Oct 09; 25(2):449-463.e4. PMID: 30304684.
      View in: PubMed
    2. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 2018 Jul 01; 78(13):3645-3658. PMID: 29760043.
      View in: PubMed
    3. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. Regulation of inside-out ß1-integrin activation by CDCP1. Oncogene. 2018 May; 37(21):2817-2836. PMID: 29511352.
      View in: PubMed
    4. Ruiz-Saenz A, Moasser MM. Targeting HER2 by Combination Therapies. J Clin Oncol. 2018 Mar 10; 36(8):808-811. PMID: 29381433.
      View in: PubMed
    5. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. PMID: 28790114.
      View in: PubMed
    6. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6912-E6921. PMID: 28760953.
      View in: PubMed
    7. Littlefield P, Moasser MM, Jura N. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell Chem Biol. 2017 07 20; 24(7):917. PMID: 28732202.
      View in: PubMed
    8. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed
    9. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. PMID: 26860947; PMCID: PMC4767608 [Available on 02/09/17].
    10. Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015 Dec 01; 6(38):41123-33. PMID: 26516700.
      View in: PubMed
    11. Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov; 1(8):1154-61. PMID: 26204261.
      View in: PubMed
    12. Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015 Dec; 14(12):2805-17. PMID: 26438156; PMCID: PMC4674361 [Available on 12/01/16].
    13. Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10(4):e0121607. PMID: 25901353.
      View in: PubMed
    14. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
      View in: PubMed
    15. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH. A multilevel model of postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2078-92. PMID: 25017248.
      View in: PubMed
    16. Moasser MM. Two dimensions in targeting HER2. J Clin Oncol. 2014 Jul 01; 32(19):2074-7. PMID: 24868026; PMCID: PMC4517047.
    17. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549; PMCID: PMC4017711.
    18. Littlefield P, Moasser MM, Jura N. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol. 2014 04 24; 21(4):453-458. PMID: 24656791; PMCID: PMC4018233.
    19. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 01; 73(3):1168-79. PMID: 23243018; PMCID: PMC3563920.
    20. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 01; 447(3):417-25. PMID: 22853430; PMCID: PMC3722874.
    21. Spassov DS, Ahuja D, Wong CH, Moasser MM. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011 Apr 29; 6(4):e19154. PMID: 21559459; PMCID: PMC3084758.
    22. Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32. PMID: 21490433; PMCID: PMC3117134.
    23. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. PMID: 21350003; PMCID: PMC4994894.
    24. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82. PMID: 21189288; PMCID: PMC3028653.
    25. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50. PMID: 20816829; PMCID: PMC2991618.
    26. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 01; 16(5):1373-83. PMID: 20179223; PMCID: PMC2831167.
    27. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. PMID: 20371474; PMCID: PMC3033659.
    28. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
    29. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65. PMID: 19349359; PMCID: PMC2671264.
    30. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 01; 15(7):2311-22. PMID: 19318475; PMCID: PMC3023342.
    31. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. PMID: 19047117.
      View in: PubMed
    32. Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76. PMID: 19037833; PMCID: PMC3031872.
    33. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 01; 415(1):97-110. PMID: 18498248; PMCID: PMC3079392.
    34. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PMID: 18410794.
      View in: PubMed
    35. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. PMID: 17968965; PMCID: PMC3024590.
    36. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec; 13(12):527-34. PMID: 17981505; PMCID: PMC3035105.
    37. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41. PMID: 17206155; PMCID: PMC3025857.
    38. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006 Jul; 54(7):1119-24. PMID: 16866685.
      View in: PubMed
    39. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006 Jun; 54(6):925-31. PMID: 16776787.
      View in: PubMed
    40. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006 Aug; 98(3):343-8. PMID: 16541322.
      View in: PubMed
    41. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11; 24(34):5333-43. PMID: 16007225; PMCID: PMC3023961.
    42. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005 Apr; 6(1):55-60. PMID: 15899073.
      View in: PubMed
    43. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar; 90(2):157-63. PMID: 15803362.
      View in: PubMed
    44. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4062-7. PMID: 15217939.
      View in: PubMed
    45. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004 Jun; 3(6):796-803. PMID: 15136770.
      View in: PubMed
    46. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 01; 9(12):4340-6. PMID: 14555504.
      View in: PubMed
    47. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. PMID: 12684394.
      View in: PubMed